Skip to main content

Table 3 Accuracy data

From: Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms

Level in % Sample conc. (µg) Std conc. (µg) Amount Std recovered % Recovery %Mean recovery
TAF
50% 5 2.5 2.49 99.62 99.87
100% 5 5 4.99 99.70  
150% 5 7.5 7.52 100.30  
COBI
50% 75 37.5 37.17 99.12 100.05
100% 75 75 75.71 100.95  
150% 75 112.5 112.59 100.1  
FTC
50% 100 50 49.99 99.98 99.53
100% 100 100 99.31 99.31  
150% 100 150 148.93 99.30  
DRV
50% 400 200 199.97 99.99 99.67
100% 400 400 399.69 99.92  
150% 400 600 594.37 99.10  
  1. Values are average of triplicate samples
  2. TAF tenofovir alafenamide, COBI cobicistat, FTC emtricitabine, DRV darunavir, μg/mL microgram/millilitre, % percentage, μg microgram